This HTML5 document contains 71 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n23http://linked.opendata.cz/resource/drugbank/drug/DB01046/identifier/national-drug-code-directory/
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n14http://linked.opendata.cz/resource/drugbank/dosage/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01046/identifier/chemspider/
n18http://bio2rdf.org/drugbank:
n24http://linked.opendata.cz/resource/drugbank/drug/DB01046/identifier/pharmgkb/
n25http://linked.opendata.cz/resource/drugbank/drug/DB01046/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n11http://linked.opendata.cz/resource/drugbank/patent/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01046/identifier/kegg-compound/
n13http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01046/identifier/pubchem-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n26http://linked.opendata.cz/resource/drugbank/medicinal-product/
n9http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n28http://www.drugs.com/cdi/
n7http://linked.opendata.cz/resource/drugbank/property/
n22http://linked.opendata.cz/resource/drugbank/drug/DB01046/identifier/kegg-drug/
n21http://linked.opendata.cz/resource/drugbank/drug/DB01046/identifier/pubchem-substance/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01046/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#
n6http://linked.opendata.cz/resource/atc/
n5http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01046
rdf:type
n3:Drug
n3:description
Lubiprostone is a medication used in the management of idiopathic chronic constipation. It is a bicyclic fatty acid (prostaglandin E1 derivative) which acts by specifically activating ClC-2 chloride channels on the apical aspect of gastrointestinal epithelial cells, producing a chloride-rich fluid secretion. These secretions soften the stool, increase motility, and promote spontaneous bowel movements (SBM).
n3:dosage
n14:271B5977-363D-11E5-9242-09173F13E4C5 n14:271B5978-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Crowell MD, Harris LA, DiBaise JK, Olden KW: Activation of type-2 chloride channels: a novel therapeutic target for the treatment of chronic constipation. Curr Opin Investig Drugs. 2007 Jan;8(1):66-70. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17263187 # Lacy BE, Chey WD: Lubiprostone: chronic constipation and irritable bowel syndrome with constipation. Expert Opin Pharmacother. 2009 Jan;10(1):143-52. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19236188 # Ambizas EM, Ginzburg R: Lubiprostone: a chloride channel activator for treatment of chronic constipation. Ann Pharmacother. 2007 Jun;41(6):957-64. Epub 2007 May 22. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17519292 # Lacy BE, Levy LC: Lubiprostone: a novel treatment for chronic constipation. Clin Interv Aging. 2008;3(2):357-64. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18686757 # Ambizas EM, Ginzburg R: Lubiprostone: a chloride channel activator for treatment of chronic constipation. Ann Pharmacother. 2007 Jun;41(6):957-64. Epub 2007 May 22. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17519292
n3:group
approved investigational
n3:halfLife
0.9 to 1.4 hours
n3:indication
For the treatment of chronic idiopathic constipation in the adult population. Also used for the treatment of irritable bowel syndrome with constipation in women who are 18 years of age or older.
owl:sameAs
n13:DB01046 n18:DB01046
dcterms:title
Lubiprostone
adms:identifier
n16:DB01046 n17:C13707 n19:571057 n20:656719 n21:46505874 n22:D04790 n23:64764-080-60 n24:PA164777012 n25:Lubiprostone
n3:mechanismOfAction
Lubiprostone acts by specifically activating ClC-2 chloride channels, which is a normal constituent of the apical membrane of the human intestine, in a protein kinase A action independent fashion. Activation of ClC-2 chloride channels causes an efflux of chloride ions into the lumen, which in turn leads to an efflux of sodium ions through a paracellular pathway to maintain isoelectric neutrality. As a result, water follows sodium into the lumen in order to maintain isotonic equilibrium, thereby increasing intestinal fluid secretion. By increasing intestinal fluid secretion, lubiprostone increases motility in the intestine, thereby increasing the passage of stool and alleviating symptoms associated with chronic idiopathic constipation. Activation of ClC-2 chloride channels may also stimulate the recovery of muscosal barrier function by restoring tight junction protein complexes in the intestine. Patch clamp cell studies in human cell lines have indicated that the majority of the beneficial biological activity of lubiprostone and its metabolites is observed only on the apical (luminal) portion of the gastrointestinal epithelium.
n3:packager
n4:271B5973-363D-11E5-9242-09173F13E4C5 n4:271B5974-363D-11E5-9242-09173F13E4C5 n4:271B5972-363D-11E5-9242-09173F13E4C5
n3:patent
n11:5317032 n11:7064148
n3:routeOfElimination
Peak plasma concentration was shown to be around 1.14 hours, with a majority of the drug excreted in the urine within 48 hours. Lubiprostone and M3 are only detected in trace amounts in human feces.
n3:synonym
Lubiprostone RU-0211 Amitiza
n3:toxicity
In a definitive Phase 1 cardiac repolarization study, 51 patients were administered a single oral dose of 144 mcg of lubiprostone, which is 6 times the normal single administration dose. Thirty-nine (39) of the 51 patients experienced an adverse event. The adverse events reported in >1% of this group included the following: nausea (45.1%), vomiting (27.5%), diarrhea (25.5%), dizziness (17.6%), loose or watery stools (13.7%), headache (11.8%), retching (7.8%), abdominal pain (5.9%), flushing or hot flush (5.9%), dyspnea (3.9%), pallor (3.9%), stomach discomfort (3.9%), syncope (3.9%), upper abdominal pain (2.0%), anorexia (2.0%), asthenia (2.0%), chest discomfort (2.0%), dry mouth (2.0%), hyperhidrosis (2.0%), skin irritation (2.0%) and vasovagal episode (2.0%).
n3:proteinBinding
94%
n3:synthesisReference
Zhijun Tang, Zhonghao Zhuo, Yunman Zheng, Bingming He, Huichun Yang, Jushang Zheng, "LUBIPROSTONE CRYSTAL, THE USE AND THE METHOD FOR THE PREPARATION THEREOF." U.S. Patent US20110028541, issued February 03, 2011.
n9:hasConcept
n10:M0493211
foaf:page
n28:lubiprostone.html
n3:IUPAC-Name
n7:271B597D-363D-11E5-9242-09173F13E4C5
n3:InChI
n7:271B5983-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n7:271B5982-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n7:271B597F-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n7:271B5980-363D-11E5-9242-09173F13E4C5
n3:SMILES
n7:271B5981-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n7:271B5993-363D-11E5-9242-09173F13E4C5 n7:271B597B-363D-11E5-9242-09173F13E4C5
n3:logP
n7:271B5994-363D-11E5-9242-09173F13E4C5 n7:271B5979-363D-11E5-9242-09173F13E4C5 n7:271B597C-363D-11E5-9242-09173F13E4C5
n3:logS
n7:271B597A-363D-11E5-9242-09173F13E4C5
n5:hasATCCode
n6:A06AX03
n3:H-Bond-Acceptor-Count
n7:271B5989-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n7:271B598A-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n7:271B5984-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n7:271B5985-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n7:271B5987-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n7:271B5986-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n7:271B5988-363D-11E5-9242-09173F13E4C5
n3:absorption
Lubiprostone has low systemic availability following oral administration and concentrations of lubiprostone in plasma are below the level of quantitation (10 pg/mL).
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
136790-76-6
n3:category
n3:containedIn
n26:271B5975-363D-11E5-9242-09173F13E4C5 n26:271B5976-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n7:271B598F-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n7:271B5991-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n7:271B5992-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n7:271B598E-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n7:271B598D-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n7:271B5990-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n7:271B597E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n7:271B598B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n7:271B598C-363D-11E5-9242-09173F13E4C5